文章核心观点 - 公司的糖尿病护理业务一直是其最佳和最稳定的增长动力之一 [1][2][3] - 公司最近推出了两款新的连续血糖监测(CGM)产品,包括面向2型糖尿病非胰岛素使用患者的Libre Rio和面向非糖尿病患者的Lingo [2][3] - 公司计划到2028年将Libre系列产品的年销售额增长到100亿美元 [3] - 公司认为CGM市场的机会巨大,因为全球有5亿成年糖尿病患者,但只有1%使用CGM技术 [4] - 公司在创新、行业经验和为长期投资者带来出色回报方面有良好记录,同时也是一家优质的股息股 [5] 文章内容总结 公司概况 - 公司的业务在过去几年一直起起伏伏,受到了疫情的影响,但通过快速开发和销售COVID-19诊断测试,弥补了医疗器械业务的损失 [1] - 公司的糖尿病护理业务一直是其最佳和最稳定的增长动力之一 [1][2][3] 新产品推出 - 公司最近推出了两款新的连续血糖监测(CGM)产品: - Libre Rio,面向2型糖尿病非胰岛素使用患者 [2] - Lingo,面向非糖尿病患者 [3] - 这些新产品是公司计划到2028年将Libre系列产品的年销售额增长到100亿美元的一部分 [3] 市场机会 - 公司认为CGM市场的机会巨大,因为全球有5亿成年糖尿病患者,但只有1%使用CGM技术 [4] - 即使在公司已有较大市场份额的国家,如美国,OTC渠道的CGM产品也可能大幅提高使用率 [4] 公司优势 - 公司在创新、行业经验和为长期投资者带来出色回报方面有良好记录 [5] - 公司连续52年增加派息,是一家优质的股息股 [5]

JHVEPhoto Introduction One of the most fascinating things about the stock market is the number of unique companies/stocks we can pick from. Especially in the United States, there seems to be a ticker for every type of business imaginable. However, this also comes with challenges. DexCom, Inc. (DXCM) is a great example of a fast-growing company that has become a disruptor in the healthcare space by offering advanced continuous glucose monitors ("CGM"). This industry is booming and resulted in a total return ...

These stocks have increased their payouts for decades.Dividend growth stocks can make for ideal investment options whether you're a retiree or a long-term investor. The types of businesses that increase their payouts on a regular basis normally have a lot of consistency in their earnings from one year to the next, making them safe investments. That doesn't mean that all dividend growth stocks are safe options, but many of them are.Three of the safer ones you can put in your portfolio today are Abbott Labora ...

Abbott (ABT) closed the latest trading day at $117.11, indicating a +0.58% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.45%. Meanwhile, the Dow lost 0.23%, and the Nasdaq, a tech-heavy index, added 0.84%.The maker of infant formula, medical devices and drugs's shares have seen an increase of 8.01% over the last month, surpassing the Medical sector's gain of 3.16% and the S&P 500's gain of 2.54%.Analysts and investors alike will be keeping a c ...

Abbott Laboratories (ABT) recently made Lingo, its continuous glucose monitoring (CGM) system, available in the United States without a prescription. The system comes with a biosensor and a mobile app designed for consumers’ overall health improvement and wellness.The latest U.S. availability of Lingo helps Abbott expand its market presence in the CGM segment.Following the news, shares of ABT fell 1.1% to $113.10 yesterday. However, as the company is gaining a high level of synergies from its continued deve ...

Abbott Laboratories announced Thursday its over-the-counter continuous glucose monitor Lingo is available in the U.S. starting at $49. Lingo is part of an emerging class of consumer-friendly biosensors that people can use to learn how their bodies respond to food, exercise, sleep and stress. These devices, called continuous glucose monitors, are small sensors that stick through the skin to measure real-time glucose levels. Glucose is a sugar molecule that comes from food, and it's the body's main energy sou ...

文章核心观点 - 公司推出了首款无需处方即可购买的连续性葡萄糖监测系统Lingo [1][2] - Lingo可以实时监测葡萄糖水平并提供个性化洞见,帮助用户建立健康习惯,重塑代谢并改善整体健康和福祉 [2] - 连续性葡萄糖监测(CGM)可以带来多方面的健康益处,如预防未来健康问题、帮助体重管理、改善睡眠和情绪等 [3] Lingo系统概述 - Lingo系统包括一个贴在手臂上的生物传感器和一款手机应用程序 [4] - 生物传感器可连续监测葡萄糖数据并传输到手机应用程序 [4] - 手机应用程序可以显示葡萄糖曲线图、Lingo计数指标、饮食和运动记录以及个性化建议 [4] Lingo产品选项 - 公司提供3种不同时长的Lingo套餐供消费者选择,分别为2周、4周和12周 [5] - 套餐价格从49美元到249美元不等,包含1-6个生物传感器 [5] 公司信息 - Lingo是雅培公司旗下的产品,该公司是全球医疗保健领导者 [7] - Lingo系统面向18岁及以上不使用胰岛素的消费者 [8]

Abbott (ABT) is experiencing strong growth in routine diagnostics owing to increased domestic and international demand. Within Established Pharmaceuticals (“EPD”), the company is driving robust growth in key therapeutic areas, advancing in the biosimilar strategy and establishing financial stability. However, the declining COVID-testing sales and currency fluctuations may restrict Abbott’s growth potential.In the past year, this Zacks Rank #3 (Hold) stock has increased 11.2% compared with the 15.5% rise of ...

The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating conditionApproximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1 ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the T ...

The most recent trading session ended with Abbott (ABT) standing at $114.66, reflecting a +1.23% shift from the previouse trading day's closing. This change outpaced the S&P 500's 2.12% loss on the day. At the same time, the Dow lost 1.51%, and the tech-heavy Nasdaq lost 3.26%.Heading into today, shares of the maker of infant formula, medical devices and drugs had gained 4.27% over the past month, lagging the Medical sector's gain of 5.45% and the S&P 500's gain of 5.78% in that time.Investors will be eager ...